期刊文献+

非小细胞肺癌患者外周血及胸水中EGFR基因突变的研究 被引量:2

EGFR gene mutation in peripheral blood and fresh hydrothorax of non-small cell lung cancer patients
下载PDF
导出
摘要 目的检测非小细胞肺癌患者外周血与新鲜胸水EGFR基因突变率及两者的一致性,探讨外周血标本在EGFR基因突变的临床应用价值。方法采用ARMS法检测51例非小细胞肺癌患者新鲜胸水及其外周血EGFR基因突变状态,比较外周血和新鲜胸水基因突变的一致性,分析EGFR基因突变与患者临床特征关系。结果 51例外周血中检出20例突变(突变率39.2%),其中19del突变11例(55%,11/20),L858R突变8例(40%,8/20),G719X突变1例(5%,1/20);新鲜胸水中检出24例突变(突变率47.1%),其中19del突变13例(54.2%,13/24),L858R突变10例(41.7%,10/24),G719X突变1例(4.1%,1/24)。两者突变一致性为80.4%(41/51),差异具有统计学意义(Kappa=0.603,P=0.000)。外周血及新鲜胸水EGFR基因突变状态均与性别、是否吸烟和病理类型有关(P<0.05),而与年龄及TNM分期无关(P>0.05)。结论非小细胞肺癌患者外周血与新鲜胸水EGFR基因突变一致性较高,在无法获得组织及细胞学标本时可以检测外周血EGFR基因状态,为非小细胞肺癌患者提供临床诊疗帮助。 Objective To detect the consistency of the EGFR gene mutation in peripheral blood and fresh hydrothorax of patients with non-small cell lung cancer and to discuss the clinical application value of EGFR gene mutation in peripheral blood.Methods Amplification refractory mutation system(ARMS)was used to detect the EGFR gene mutation in fresh hydrothorax and the peripheral blood of 51 patients with non-small cell lung cancer,and their consistency was compared.And the correlation was analyzed between EGFR gene mutation and clinical characteristics of the patients.Results The EGFR gene mutation rate was 39.2%in peripheral blood in 51 patients with non-small cell lung cancer,and it was 47.1%in fresh hydrothorax.In peripheral blood,there were 11 cases(55%,11/20)of exon 19 deletion mutation,8 cases(40%,8/20)of exon 21 missense mutation(L858R)and 1 cases(5%,1/20)of exon 18 missense mutation(G719X).In fresh hydrothorax,there were 13 cases(54.2%,13/24)of exon 19 deletion mutation,10 cases(41.7%,10/24)of exon 21 missense mutation(L858R)and 1 cases(4.1%,1/24)of exon 18 missense mutation(G719X).The mutation consistency was 80.4%between the two matched samples.There were significantly statistical differences(Kappa=0.603,P=0.000).The EGFR mutation in peripheral blood and fresh hydrothorax was related with gender,smoking history and histological type(P<0.05),but not with age and clinical stages(P>0.05).Conclusion The consistency of the EGFR gene mutation in peripheral blood and fresh hydrothorax is high.EGFR gene mutation of peripheral blood could be used for clinical diagnosis and treatment in cases when tissue and cytological specimens are unavailable.
作者 张艳 杜芸 郭晓凯 王蕊 吴娟 纪晓坤 郭晓 马阳 赵银环 ZHANG Yan;DU Yun;GUO Xiao-kai;WANG Rui;WU Juan;JI Xiao-kun;GUO Xiao;MA Yang;ZHAO Yinhuan(Cancer Detection Center of the Fourth Affiliated Hospital of Hebei Medical University,Shijiɑzhuɑnɡ050011,Hebei,China;Chest Hospital of Hebei Province,Shijiɑzhuanɡ050011,Hebei,China)
出处 《诊断病理学杂志》 2019年第9期566-569,573,共5页 Chinese Journal of Diagnostic Pathology
基金 河北省卫生厅医学科学研究重点课题计划(20150777),河北省卫生厅医学科学研究重点课题计划(20180557)
关键词 非小细胞肺癌 EGFR基因 突变 外周血 新鲜胸水 ARMS Non-small cell lung cancer EGFR gene Mutation Peripheral blood Hydrothorax Amplification refractory mutation system(ARMS)
  • 相关文献

参考文献4

二级参考文献39

  • 1何臣,刘明,周承志,徐军.非小细胞肺癌患者外周血表皮生长因子受体基因突变的检测及临床意义[J].中国呼吸与危重监护杂志,2011,10(3):273-277. 被引量:6
  • 2Paez JG, Janne PA, Lee JC, et al. EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy. Science, 2004, 304(5676): 1497-1500.
  • 3Lynch TJ, Bell DW, Sordella R, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non- small-cell lung cancer to gefitinib. N Engl J Med, 2004, 350(21): 2129-2139.
  • 4Fukuoka M, Yano S, Giaccone G, et alo Multi-Institutional Randomized Phase Ⅱ Trial of Gefitinib for Previously Treated Patients With Advanced Non - Small-Cell Lung Cancer. J Clin Oncol, 2003, 21(12): 2237-2245.
  • 5Kris MG, Natale RB, Roy SH, et al. Efficacy of Gefitinib, an Inhibitor of the Epidermal Growth Factor Receptor Tyrosine Kinase, in Symptomatic Patients With Non-Small Cell Lung Cancer: A Randomized Trial. JAMA, 2003, 290(16): 2149-2158.
  • 6Chan SK, Gullick WJ, Hill ME. Mutations of the epidermal growth factor receptor in non-small cell lung cancer-search and destroy. Eur J cancer, 2006, 42(1): 17-23.
  • 7Ohnishi H, Ohtsuka K, Ooide A, et al. A simple and sensitive method for detecting major mutations within the tyrosine kinase domain of the epidermal growth factor receptor gene in non-small-cell lung carcinoma. Diagn Mol Pathol, 2006, 15(2): 101-108.
  • 8Asano H, Toyooka S, Tokumo M, et al. Detection of EGFR Gene Mutation in Lung Cancer by Mutant-Enriched Polymerase Chain Reaction Assay. Clin Cancer Res, 2006, 12(1): 43-48.
  • 9Nagai Y, Miyazawa H, Qun H, et al. Genetic Heterogeneity of the Epidermal Growth Factor Receptor in Non - Small Cell Lung Cancer Cell Lines Revealed by a Rapid and Sensitive Detection System, the Peptide Nucleic Acid-Locked Nucleic Acid PCR Clamp. Cancer Res, 2005, 65(16): 7276 - 7282.
  • 10Endo K, Konishi A, Sasaki H, et al. Epidermal growth factor receptor gene mutation in non-small cell lung cancer using highly sensitive and fast TaqMan PCR assay. Lung Cancer, 2005, 50(3): 375-384.

共引文献41

同被引文献19

引证文献2

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部